I looked over the report and while its long it repeats a lot! Seems to be a lot of the company line/presentation. Only thing I caught of interest which perhaps I missed OCRX disclosing at some point is this about the NIH study
The other thing in their modeling they use a $6,500 price for 5 day treatment. For the oral they model $1600/mo and say that is comparable to Xifaxan. There is also a nice table of IP (page 23).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.